Mazen Noureddin MD MHSc
Hepatology & Liver Transplantation
Transplant Hepatologist, Houston Methodist Hospital, Director Houston Research Institute
Join to View Full Profile
1155 Dairy Ashford RoadSte 200Houston, TX 77079
Phone+1 281-809-3234
Fax+1 281-809-3287
Dr. Noureddin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke School of MedicineMHSc, Master's Health Sciences in Clinical Research, 2009 - 2018
University of California (San Diego) Medical CenterFellowship, Gastroenterology, 2011 - 2013
Clinical Center at the National Institutes of HealthFellowship, Transplant Hepatology, 2009 - 2011
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2005 - 2008
University of Aleppo Faculty of MedicineClass of 2002
Certifications & Licensure
TX State Medical License 2022 - 2027
CA State Medical License 2007 - 2025
VA State Medical License 2008 - 2012
American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Top Doctors Pasadena Magazine 2014-2018
- Visionary in Health Care American Liver Foundation, 2016
Clinical Trials
- The Effect of Acetaminophen on Non-alcoholic Fatty Liver Disease Patients Start of enrollment: 2014 Jun 01
- Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis Start of enrollment: 2015 Jun 01
Publications & Presentations
PubMed
- MetALD: New Perspectives on an Old Overlooked Disease.Gustavo Ayares, Luis Antonio Diaz, Francisco Idalsoaga, Naim Alkhouri, Mazen Noureddin
Liver International. 2025-05-01 - Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial ...Wee Han Ng, Yee Hui Yeo, Hyunseok Kim, Ekihiro Seki, Jonathan Rees
Hepatology. 2025-04-02 - Agile 3+ and 4 Scores Accurately Predict Major Adverse Liver Outcomes, Liver Transplant, Progression of MELD Score, the Development of Hepatocellular Carcinoma, and De...Emily Truong, Lynna Alnimer, Jeffrey A Gornbein, Ju Dong Yang, Naim Alkhouri
Digestive Diseases and Sciences. 2025-03-24
Journal Articles
- NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances.Noureddin M1,2, Vipani A3, Bresee C4, Todo T5, Kim IK5, Alkhouri N6, Setiawan VW7, Tran T8,3, Ayoub WS8,3, Lu SC8,3, Klein AS5, Sundaram V8,3, Nissen NN5., American Journal of Gastrenterology, 6/8/2018
- NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications for Liver Transplant and Ethnic and Gender VariancesTsuyoshi Todo, Walid S Ayoub, Naim Alkhouri, Nicholas N Nissen, Vinay Sundaram, Shelly C Lu, Mazen Noureddin, Aarshi Vipani, Tram Tran, Andrew S Klein, Nature
Press Mentions
Resmetirom with Weight Loss Improves MASH, FibrosisMarch 6th, 2025- Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (Resmetirom) in Patients with Compensated MASH CirrhosisFebruary 26th, 2025
- Hot-Button Issues: Experts Share Opinions on Shifts in Clinical Innovation, Policy in 2024December 30th, 2024
- Join now to see all
Other Languages
- Arabic, Farsi, Spanish
External Links
- Houston Methodist Hospitalhttps://www.houstonmethodist.org/doctor/mazen-noureddin/
- Houston Research Institute https://www.houstonresearchinstitute.com/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
